1. Home
  2. BVS vs ACRS Comparison

BVS vs ACRS Comparison

Compare BVS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$13.63

Market Cap

982.2M

Sector

Health Care

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.70

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVS
ACRS
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
982.2M
868.5M
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
BVS
ACRS
Price
$13.63
$5.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$14.00
$10.20
AVG Volume (30 Days)
460.2K
2.4M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
163.46
69.01
EPS
0.52
N/A
Revenue
$568,087,000.00
$1,683,000.00
Revenue This Year
$7.52
N/A
Revenue Next Year
$7.06
$4.24
P/E Ratio
$26.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.26
$1.74
52 Week High
$15.89
$6.60

Technical Indicators

Market Signals
Indicator
BVS
ACRS
Relative Strength Index (RSI) 50.84 45.36
Support Level $13.44 $4.13
Resistance Level $14.71 $5.87
Average True Range (ATR) 0.51 0.33
MACD -0.08 -0.05
Stochastic Oscillator 51.85 45.56

Price Performance

Historical Comparison
BVS
ACRS

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: